Nusinersen vs Risdiplam (Evrysdi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Spinal Muscular Atrophy

Shared mechanism: SMN2 pre-mRNA · full Spinal Muscular Atrophy pipeline

Nusinersen · Spinraza

Marketed by Biogen and partners

Approved in Spinal Muscular Atrophyantisense
Weak signal

NCT01839656 · Phase 2 · completed

The study was nonrandomized, open-label, and lacked a placebo or active comparator; it enrolled 21 participants, with 20 treated and analyzed. Its clinical motor milestone endpoint was reported descriptively by dose group, but no formal controlled primary comparison was applicable, so the findings provide limited evidence that nusinersen caused the observed improvements.

Next expected readout: September 2027 · NCT05067790 (registry estimate)

Reported efficacy

Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9) (met)

Result source: NCT02292537

Risdiplam (Evrysdi)

Marketed by Roche and partners

Approved in Spinal Muscular Atrophysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT05861999 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Spinal Muscular Atrophy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Risdiplam (Evrysdi): registry results are on file for Spinal Muscular Atrophy, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nusinersen
Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit (Day 1352 or Early Termination): Nusinersen 6 mg 25 Percent of participants | Nusinersen 12 mg 68.8 Percent of participants NCT01839656 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result
Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15 (Baseline and Month 15): Sham Procedure -1 scores on a scale (95% CI -2.5 to 0.5) | Nusinersen 3.9 scores on a scale (95% CI 3 to 4.9) NCT02292537 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nusinersen's landscape · Risdiplam (Evrysdi)'s landscape